Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
64 巻, 11 号
選択された号の論文の34件中1~34を表示しています
ORIGINAL ARTICLES
  • Yuko Ishimaru, Takaomi Kessoku, Michihiro Nonaka, Yoichiro Kitajima, H ...
    2025 年 64 巻 11 号 p. 1612-1622
    発行日: 2025/06/01
    公開日: 2025/06/01
    [早期公開] 公開日: 2024/11/01
    ジャーナル オープンアクセス

    Objective Myosteatosis affects the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD) and may be a potential therapeutic target. This study aimed to examine the effects of ipragliflozin (IPR) on myosteatosis in patients with type 2 diabetes mellitus (T2D) and MASLD.

    Methods Patients were treated with IPR group or a control (CTR) group for 72 weeks in a randomized trial. Changes in myosteatosis of the lumbar skeletal muscles were evaluated using computed tomography. The response of myosteatosis to treatment and the baseline characteristics of the patients were analyzed.

    Patients 44 participants (IPR group, 23; CTR group, 21) with MASLD complicated by T2D.

    Results Myosteatosis increased in the CTR group (n=21) but remained unchanged in the IPR group (n=23). The changes were apparent at 24 weeks (p=0.004), but were not significant after 24 weeks. A hierarchical cluster analysis was performed to identify clusters with and without improvement in myosteatosis. The clusters with decreasing intramuscular adipose tissue content (IMAC) at 48 and 72 weeks were not treated, but they had lower visceral fat area and severe liver steatosis at baseline. Improvements in glycemic control and resistance to decreasing abdominal skeletal muscle area from baseline to 24 weeks affected the decrease in IMAC at 48 and 72 weeks.

    Conclusion Ipragliflozin had a limited effect on skeletal muscle adiposity in patients with T2D and MASLD. Regardless of the treatment, a specific phenotype of adiposity and hepatic steatosis before treatment is associated with the long-term outcomes of myosteatosis. Maintaining skeletal muscle mass and better glycemic control during treatment are essential for the future improvement of myosteatosis.

  • Masamitsu Kido, Ken Inoue, Reo Kobayashi, Naoyuki Takashima, Katsutosh ...
    2025 年 64 巻 11 号 p. 1623-1632
    発行日: 2025/06/01
    公開日: 2025/06/01
    [早期公開] 公開日: 2024/11/01
    ジャーナル オープンアクセス

    Objective Digital evacuation (DE) is an intervention used to address severe constipation. Literature exists on easily administered laxatives; however, reports on mildly invasive DE usage are limited. This study aimed to elucidate the fundamental data regarding constipation management using a comprehensive national database of DE incidence.

    Methods This observational epidemiological study analyzed the age- and sex-stratified DE incidence per 1,000 person-years during 2014-2021 using the medical receipt database in Japan. The annual trends were evaluated using Poisson regression models. We examined the month-stratified incidence during 2019-2021 to assess potential seasonal variations using a one-way analysis of variance and unpaired t-tests with the Bonferroni correction for comparisons across the four seasons. Correlation coefficients were calculated to determine the relationship between the meteorological variables and DE incidence.

    Results Over the 8-year period, the DE incidence amounted to 32,361,846 procedures, with a median of 10.3 procedures per 1,000 person-years. A demographic analysis revealed a minor peak, nadir, and progressive increase peaking in the 0-4-year (22.1 procedures), 5-9-year (1.5 procedures), and ≥90-year (370.7 procedures) age groups, respectively. The age-adjusted DE incidence across all age groups per 1,000 person-years showed a declining annual trend [incidence rate ratio: 0.971 (p<0.0001)]. A seasonal analysis revealed a significant increase in DE procedures during winter compared with summer (p<0.0125). A correlation was observed between the DE incidence and certain meteorological variables, particularly the temperature.

    Conclusion This study highlights the notable demographic patterns and the impact of seasonal and meteorological factors on the DE incidence.

  • Yuichi Shimodate, Akiko Shiotani, Ken-ichi Tarumi, Hiroshi Matsumoto, ...
    2025 年 64 巻 11 号 p. 1633-1639
    発行日: 2025/06/01
    公開日: 2025/06/01
    [早期公開] 公開日: 2024/11/08
    ジャーナル オープンアクセス

    Objective To investigate the clinical course of ulcerative colitis (UC) during pregnancy, focusing on their mutual influence.

    Methods We retrospectively reviewed the medical records of 58 patients with UC who had 73 pregnancies and 3 patients with newly developed UC during pregnancy. We recorded the rate of relapse of UC; the relationship between medication use and UC relapse during pregnancy; treatment for relapse; and the incidence of pregnancy, childbirth, and newborn abnormalities.

    Results UC was in remission at conception in 78% of the patients. The relapse rate during pregnancy was 27.3%, with most relapses occurring during the second and third trimesters. The relapse rate in patients in whom any UC drug had been discontinued was 50%, a rate significantly higher than the 20.5% of patients for whom all medications were continued (p=0.016). Thiopurine was discontinued in 60% (6/10) of patients at conception, and the disease relapsed in 50% (3/6) of the patients. Most relapses were successfully treated with 5-aminosalicylic acid or corticosteroids. UC relapse occurred in 26.1% (18/70) of the patients after delivery, mostly within 2 months. Pregnancy, delivery, or neonatal abnormalities occurred in 23.3% (17/73) of patients. In two of the three patients with new-onset UC, UC was severe and required intensive care; however, the pregnancies continued uneventfully.

    Conclusion Although the progress of pregnancies complicated by UC was mostly uneventful, discontinuing medication carries the risk of UC relapse. Thus, appropriate management of medical treatments for UC during pregnancy is important.

  • Tetsuo Furukawa, Isamu Mizote, Tatsuya Shiraki, Daisuke Nakamura, Mayu ...
    2025 年 64 巻 11 号 p. 1640-1647
    発行日: 2025/06/01
    公開日: 2025/06/01
    [早期公開] 公開日: 2024/11/08
    ジャーナル オープンアクセス
    電子付録

    Objective Recent guidelines recommend dual antiplatelet therapy (DAPT) for six months following percutaneous coronary intervention (PCI) in patients with chronic coronary disease, as unexpected hospitalization can trigger DAPT discontinuation. This study evaluated the predictive factors for unexpected hospitalization within six months after PCI in patients with chronic coronary disease.

    Methods This prospective multicenter study included 412 patients who underwent PCI for chronic coronary disease. Unexpected hospitalization was defined as a prolonged hospital stay, unscheduled readmission, and all-cause mortality. The predictive factors for unexpected hospitalization within six months post-PCI were evaluated using the Cox regression model.

    Results The rate of unexpected hospitalization 6 months after PCI was 10.8%±1.5%. Unexpected hospitalizations due to bleeding events accounted for 12.1% (n=5/41), whereas non-bleeding readmissions accounted for 87.9% (n=36/41). A multivariable analysis revealed that the number of Academic Research Consortium for High Bleeding Risk (ARC-HBR) major criteria met [adjusted hazard ratio (HR), 1.55; 95% confidence interval (CI), 1.05-2.29; p=0.026], body weight (adjusted HR, 2.44; 95% CI 1.33-4.49; p=0.004), and presence of diabetes mellitus (adjusted HR, 1.94; 95% CI 1.09-3.47; p=0.025) were independent risk factors for unexpected hospitalization. Among the major ARC-HBR criteria, oral anticoagulant use (adjusted HR, 2.39; 95% CI, 1.14-5.02, p=0.021) and active malignancy (adjusted HR, 3.85; 95% CI, 1.47-10.05; p=0.006) were significantly associated with unexpected hospitalization after adjusting for a low body weight and diabetes mellitus.

    Conclusions The majority of unexpected hospitalizations after PCI in patients with chronic coronary disease are attributed to non-bleeding causes. The assessment using major ARC-HBR criteria in these patients not only addresses bleeding risks but also underscores its predictive value in conjunction with a low body weight and diabetes mellitus for the prediction of unexpected hospitalization.

  • Kensuke Sumi, Tomomasa Tsuboi, Yuichi Chihara, Nobuhiro Okagaki, Kaori ...
    2025 年 64 巻 11 号 p. 1648-1652
    発行日: 2025/06/01
    公開日: 2025/06/01
    [早期公開] 公開日: 2024/10/25
    ジャーナル オープンアクセス

    Objective Obstructive sleep apnea syndrome (OSAS) causes multiple breathing interruptions during sleep and increases mortality if left untreated. Continuous positive airway pressure (CPAP) therapy improves the prognosis of OSAS; however, patient adherence is often poor. This study investigated the relationship between monthly hospital visits and CPAP adherence to CPAP therapy in patients with OSAS.

    Methods We studied 119 patients (93 men and 26 women) at the Minami Kyoto Hospital between June 2022 and May 2023. CPAP adherence was measured daily. Hospital/clinic visits were categorized as "Last minute visits at the end of the month" (≥25th of the month) and analyzed in relation to CPAP adherence.

    Results The average duration of CPAP use duration were 5 h, 47 min, and 43 s. Patients visiting on or after the 25th of month had significantly lower CPAP use (4 h 17 min 05 s) compared to those visiting before the 25th of month (6 h 01 min 47 s, p=0.003). No significant correlation was found between the visit frequency and adherence to CPAP therapy, with a lower visit frequency unexpectedly corresponding to longer CPAP use (p=0.04).

    Conclusion The timing of monthly clinic visits significantly affected CPAP adherence, with late-month visits associated with poorer adherence. Visit frequency showed no clear correlation with adherence, suggesting that other factors may have influenced CPAP use. Further supportive interventions can enhance adherence and improve the treatment outcomes.

CASE REPORTS
PICTURES IN CLINICAL MEDICINE
LETTERS TO THE EDITOR
feedback
Top